Showing 7501-7510 of 10465 results for "".
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel P
- Data Indicate Need to Critically Assess Sunscreen Formulationshttps://practicaldermatology.com/news/20131107-data_indicate_need_to_critically_assess_sunscreen_formulations/2459419/When it comes to sunscreen selection, consumers may benefit from an assessment of a product's specific formulation rather than simply a “Broad Spectrum” claim, according to a poster presented at last month's Fall Clinical Dermatology Conference (Ouyang, et al.). The poster analyzed the critical wave
- Cosmetic Surgery Forum Announces Innovators in Dermatology Recipientshttps://practicaldermatology.com/news/20131107-cosmetic_surgery_forum_announces_innovators_in_dermatology_recipients/2459420/The upcoming Cosmetic Surgery Forum (www.cosmeticsurgeryforum.com), taking place at the ARIA Resort and Casino in Las Vegas from December 5-7, recently announced the recipients of its “Innovators in Dermatology” presentation. Among those honored this year will be Jim Hartman, Vice President of US Ae
- FDA Clears Fish-Skin Technology to Heal Human Woundshttps://practicaldermatology.com/news/20131107-fda_clears_fish-skin_technology_to_heal_human_wounds/2459421/Kerecis Limited announced has received FDA 510(k) clearance from the Food and Drug Administration (FDA) to market a proprietary fish-skin, Omega3, tissue-regeneration technology for the treatment of chronic wounds in the US. The technology, marketed under the name MariGen Omega3, is indicated for th
- MELA Sciences Appoints Rose Crane as President and Chief Executive Officer and a Directorhttps://practicaldermatology.com/news/20131106-mela_sciences_appoints_rose_crane_as_president_and_chief_executive_officer_and_a_director/2459422/MELA Sciences, Inc. (MELA), the medical device company that has developed and is commercializing MelaFind(R), an optical diagnostic device using proprietary technology that enables dermatologists to “see” below the surface of a patient's skin to aid in the diagnosis of melanoma, today announced that
- Suneva Medical Announces Expansion Of Its ReGenica Distribution Partnership With Obagi Medical Productshttps://practicaldermatology.com/news/20131101-suneva_medical_announces_expansion_of_its_regenica_distribution_partnership_with_obagi_medical_product/2459424/Suneva Medical, Inc., recently announced plans to expand its existing partnership with Obagi Medical Products, Inc. Suneva Medical distributes, and is the exclusive licensee for, the full line of ReGenica skincare produ
- Subliminally Exposed to be Presented at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20131029-subliminally_exposed_to_be_presented_at_cosmetic_surgery_forum/2459426/Based on the New York Times and USA Today best seller, Subliminally Exposed, Dr. Steven Dayan and Valerie Monroe will present at this year's Cosmetic Surgery Fo
- New Stelara Data Show Inhibition Of Joint Destruction In Psoriatic Arthritis Patientshttps://practicaldermatology.com/news/20131029-new_stelara_data_show_inhibition_of_joint_destruction_in_psoriatic_arthritis_patients/2459427/New findings from two integrated Phase III Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with ustekinumab (Stelara) resulted in
- Restoration Robotics Announces the Launch Of ARTAS Hair Studio™https://practicaldermatology.com/news/20131025-restoration_robotics_announces_the_launch_of_artas_hair_studio/2459428/At this year's International Society of Hair Restoration Surgery (ISHRS) conference in San Francisco (October 23-27), Restoration Robotics will introduce the ARTAS Hair Studio™, a new product that expands the clinical indication and capability o
- Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticumhttps://practicaldermatology.com/news/20131024-auxilium_pharmaceuticals_inc_announces_first_patient_dosed_in_phase_2a_cellulite_study_of_collegenase_clostridium_histolyticum/2459430/Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced the first patient dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known